Business
Why the Immutep (ASX:IMM) share price will be in focus today
Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents.
Immutep is a global biotech that is focused on developing immunotherapy therapies for cancer and autoimmune diseases. Its lead product, eftilagimod alpha, is a soluble LAG-3Ig fusion protein based on the LAG-3 which is in clinical development.
New patent added
The Immutep share price could be on the move today following the company’s latest update released after yesterday’s market close
According to its…
-
Noosa News14 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer
-
General13 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
General11 hours agoNew Zealand wants more ‘automated decision-making’ in its welfare system. Could that lead to Robodebt 2.0?
-
Noosa News16 hours agoQueensland set for ‘comfortable’ weather over Easter long weekend